The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol "4C-DES"


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Patient with clopidogrel resistance with treatment of dual antiplatelet agent, aspirin and clopidogrel, for more than 4 weeks after drug-eluting stent
- Clopidogrel resistance is defined as a patients with platelet inhibition less than 30% in platelet function test(VerifyNow-P2Y12 assayTM, Accumetrics, San Diego, CA, USA)

Exclusion Criteria

- Acute myocardial infarction within 2 weeks
- Unstable angina within 2 weeks
- History of using glycoprotein IIb/IIIa inhibitor within 1 month
- Cerebral infarction within 3 months
- Bleeding diathesis like coagulation disorder, thrombocytopenia (platelet count < 100,000/uL)
- history of gastrointestinal bleeding or genitourinary bleeding within 3 months
- needed oral anticoagulation
- aspirin, clopidogrel or cilostazol hypersensitivity
- congestive heart failure
- serum creatinine level >2mg/dl
- malignancy
- using cytochrome P450 inhibitor (eg, itraconazole)